Drugs & Side Effects | COX-2 / Arthritis

Vioxx News

Merck Response to New England Journal of Medicine Retraction

RSS News Feeds
Drugs & Pharmacuticals
Stroke
Vioxx
 All RSS Feeds

At a glance:

From the "if I say it, that makes it so" file, the drugmaker Merck continues to insist that studies originally reported in the New England Journal of Medicine are still valid despite a correction issued by that publication. 
 
The Journal retracted the part of the article that concluded that Vioxx heart risk only begins after 18 months of use, after data was re-analyzed. 
 
Merck still insists it will fight the over 11,000 Vioxx liability lawsuits one at a time.

Merck says Vioxx risk unchanged by data correction

Reuters - 6/26/2006 3:58 PM

NEW YORK, June 26 (Reuters) - Merck & Co said on Monday that it stands by the original findings of the study that led to the withdrawal of its pain drug Vioxx from the market, despite a correction to the description of how some of the data were analyzed.
 
Merck said it still believes the data from the study confirms that the increased risk of heart attack and stroke from Vioxx begins only after the medicine has been taken for 18 months, although the New England Journal of Medicine cast doubts on that conclusion earlier on Monday
 
· Read The Full Vioxx Article From Reuters -->

· Read All Vioxx (Rofecoxib) News Stories -->

Comments On Vioxx News Articles:


No Current Comments
Posted by Admin on 3/20/2006

There are no current comments. Why not post one?

Leave a Comment:

Once you click the 'Save Comment' button, you will receive a verification email from our website. Be sure to change any spam settings to allow webmaster@lawsuitsearch.com as a trusted sender.
 
If you are already a member, you can Sign In Here.
 
You can create your own FREE user account that you can use to participate in our message boards, blogs, newsletters and other community activities such as this one. To get your FREE user account, click here.

Email Address:

Your Name:

Message Title:

Message: